Table 6.
Adverse events (>10%) during treatment with sorafenib after lenvatinib in patients with advanced HCC
| Events | Sorafenib (n = 53) | |
|---|---|---|
| any (%) | grade ≥3 (%) | |
| Aspartate aminotransferase increased | 31 (58.5) | 6 (11.3) |
| Hypertension | 26 (49.l) | 1 (1.9) |
| Hypoalbuminemia | 25 (47.2) | 0 |
| Proteinuria | 20 (37.7) | 6 (11.3) |
| Fatigue | 16 (30.2) | 0 |
| Thrombocytopenia | 15 (28.3) | 1 (1.9) |
| Bilirubin increased | 14 (26.4) | 2 (3.8) |
| Hemolysis | 14 (26.4) | 1 (1.9) |
| Palmar-plantar erythrodysesthesia | 13 (24.5) | 1 (1.9) |
| Anorexia | 13 (24.5) | 0 |
| Serum amylase increased | 9 (17.0) | 2 (3.8) |
| Diarrhea | 7 (13.2) | 1 (1.9) |
| Erythema multiform | 6 (11.3) | 2 (3.8) |
| Alopecia | 4 (7.5) | 0 |
| Hypothyroidism | 4 (7.5) | 0 |
| White blood cell count decreased | 4 (7.5) | 1 (1.9) |
| Encephalopathy | 3 (5.7) | 0 |
HCC, hepatocellular carcinoma.